At what prices were Harold Bernstein’s MAZE share sales executed?

Bernstein’s 13,253-share sale used a weighted average price of $25.5746 per share, from trades between $25.16 and $26.10. His 1,600-share sale used a weighted average of $26.3576, from trades between $26.16 and $26.53, as disclosed in the footnotes.

Were Harold Bernstein’s MAZE share sales part of a Rule 10b5-1 plan?

The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such pre-arranged plans schedule trades in advance, indicating these sales followed a predetermined program rather than discretionary timing decisions by the executive.

Maze Therapeutics (MAZE) CMO sells 14,853 shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 14,853 shares of common stock at an exercise price of $10.42 per share, then sold all 14,853 shares in open-market transactions at weighted average prices of $25.57 and $26.36 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan, and he reported no directly held common shares afterward while retaining 207,554 stock options following the option exercise.

Insider Trade Summary 10b5-1

Net Seller: 14,853 shares ($381,112)

Net Sell 4 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 14,853 shs ($381K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	14,853	$0.00	--
Exercise	Common Stock	14,853	$10.42	$155K
Sale	Common Stock	13,253	$25.5746	$339K
Sale	Common Stock	1,600	$26.3576	$42K

Holdings After Transaction: Stock Option (Right to Buy) — 207,554 shares (Direct, null); Common Stock — 14,853 shares (Direct, null)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Shares sold: 14,853 shares First sale size and price: 13,253 shares at $25.5746/share Second sale size and price: 1,600 shares at $26.3576/share +3 more

6 metrics

Shares sold 14,853 shares Total Maze Therapeutics common stock sold on open market

First sale size and price 13,253 shares at $25.5746/share Weighted average sale price; trades between $25.16 and $26.10

Second sale size and price 1,600 shares at $26.3576/share Weighted average sale price; trades between $26.16 and $26.53

Options exercised 14,853 shares at $10.42/share Stock option exercise price for Maze Therapeutics common stock

Options remaining 207,554 stock options Stock options outstanding after partial exercise

Option expiration 2032-10-26 Expiration date for the reported stock option award

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 05:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		M⁽¹⁾		14,853	A	$10.42	14,853	D
Common Stock	06/01/2026		S⁽¹⁾		13,253	D	$25.5746⁽²⁾	1,600	D
Common Stock	06/01/2026		S⁽¹⁾		1,600	D	$26.3576⁽³⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$10.42	06/01/2026		M⁽¹⁾			14,853	⁽⁴⁾	10/26/2032	Common Stock	14,853	$0	207,554	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive.

4. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MAZE executive Harold Bernstein report?

Harold Bernstein reported exercising stock options for 14,853 Maze Therapeutics shares and immediately selling all 14,853 shares in open-market transactions. The activity reflects an exercise-and-sell pattern rather than a new open-market purchase, and was executed under a Rule 10b5-1 trading plan.

How many Maze Therapeutics (MAZE) shares did Harold Bernstein sell?

Harold Bernstein sold a total of 14,853 Maze Therapeutics common shares. The sales occurred in two open-market transactions, one for 13,253 shares and another for 1,600 shares, at weighted average prices in the mid-$20s per share, following his option exercise.

What was the stock option exercise price in Harold Bernstein’s MAZE Form 4?

Bernstein exercised stock options covering 14,853 Maze Therapeutics shares at an exercise price of $10.42 per share. The options were part of an award that vested over time, with vesting beginning on October 3, 2023, subject to his continued service with the company.

Does Harold Bernstein still hold Maze Therapeutics stock options after these transactions?

Yes. After exercising 14,853 options, Bernstein reported 207,554 stock options remaining. These options relate to Maze Therapeutics common stock and have an exercise price of $10.42 per share, with an expiration date in 2032, based on the derivative transaction entry.